VPAS: Progress two years in and opportunities to improve over next three yearsIn the final instalment of our series reviewing the the 2019 Voluntary Scheme for Branded Medicines Pricing and Share XVPAS: Progress two years in and opportunities to improve over next three yearshttps://pharmaphorum.com/views-analysis-market-access/vpas-progress-two-years-in-and-opportunities-to-improve-over-next-three-years/
VPAS: Achievement so far on objectives for the economy and innovationIn the third part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Share XVPAS: Achievement so far on objectives for the economy and innovationhttps://pharmaphorum.com/views-analysis-market-access/vpas-achievement-so-far-on-objectives-for-the-economy-and-innovation/
VPAS: Achievements so far on affordabilityIn the second part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing Share XVPAS: Achievements so far on affordabilityhttps://pharmaphorum.com/views-analysis-market-access/vpas-achievements-so-far-on-affordability/
VPAS: Achievement so far on objectives for patientsThe UK has a voluntary agreement that was struck by the government and NHS England (now referred to Share XVPAS: Achievement so far on objectives for patientshttps://pharmaphorum.com/views-analysis-market-access/vpas-achievement-so-far-on-objectives-for-patients/
2021 – UK market access prospectsWith a new year comes the opportunity to think ahead for the market access landscape for the coming Share X2021 – UK market access prospectshttps://pharmaphorum.com/views-analysis-market-access/2021-uk-market-access-prospects/
Simple steps to better communicate NHS medicines spendLeela Barham says that there’s a communication problem when it comes to one of the most important and Share XSimple steps to better communicate NHS medicines spendhttps://pharmaphorum.com/views-analysis-market-access/simple-steps-better-communicate-nhs-medicines-spend/
An alternative set of metrics for the UK’s pricing and access dealLeela Barham takes a look at alternative ways pharma and the UK government could measure progress for the Share XAn alternative set of metrics for the UK’s pricing and access dealhttps://pharmaphorum.com/views-and-analysis/an-alternative-set-of-metrics-for-the-uks-pricing-and-access-deal/
VPAS 2024: What should industry consider next time?The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded Share XVPAS 2024: What should industry consider next time?https://pharmaphorum.com/views-analysis-market-access/vpas-2024-what-should-industry-consider-next-time/
